- ►ahajournals.org JD Brown, J Plutzky - Circulation, 2007 - Am Heart Assoc Peroxisome proliferator–activated receptors (PPARs) are ligand-activated
transcription factors involved in the transcriptional regulation of key
metabolic pathways such as lipid metabolism, adipogenesis, and insulin ... Cited by 104 - Related articles - All 8 versions
A Rubenstrunk, R Hanf, DW Hum, JC Fruchart, … - BBA-Molecular and Cell Biology of Lipids, 2007 - Elsevier Because of their wide range of actions on glucose homeostasis, lipid metabolism
and vascular inflammation, peroxisome proliferator-activated receptors (PPARs)
are promising targets for the development of new drugs for the treatment of ... Cited by 56 - Related articles - All 3 versions
CJ Tack, P Smits - Neth J Med, 2006 - njmonline.nl Pioglitazone and rosiglitazone, two oral blood glucose lowering drugs for the
treatment of type 2 diabetes mellitus, have been marketed in the Netherlands
since 2000. Both belong to the class of thiazolidinedione derivatives ... Cited by 16 - Related articles - View as HTML - All 7 versions
J Karalliedde, RE Buckingham - Drug Safety, 2007 - ingentaconnect.com Thiazolidinediones (TZDs) or glitazones are agents that are widely used for the
Abstract treatment of type 2 diabetes mellitus. These drugs have a multitude of
therapeutic effects including reduction in insulin resistance and ... Cited by 15 - Related articles - BL Direct - All 6 versions
SY Yuan, JW Breslin, R Perrin, N Gaudreault … - Microcirculation, 2007 - informahealthcare.com Microvascular barrier injury has been implicated in the initiation and progress
of end organ complications of diabetic mellitus. Plasma leakage and fluid
retention are seen in various tissues of diabetic patients or animals at ... Cited by 13 - Related articles - BL Direct - All 4 versions
RE Buckingham, A Hanna - Diabetes Obes Metab, 2008 - pt.wkhealth.com Thiazolidinediones (TZDs) are relatively new agents for the treatment of type 2
diabetes. They act as agonists at the PPAR-γ nuclear receptor and their
therapeutic effects include decreased insulin resistance and ... Cited by 8 - Related articles - All 5 versions
S Tiwari, ER Blasi, JR Heyen, AD McHarg, … - Pharmacological Research, 2008 - Elsevier Peroxisome-proliferator-activated receptor (PPAR-γ) agonists improve insulin
sensitivity, but are associated with edema. Increased distal tubule sodium and
water reabsorption through the epithelial sodium channel (ENaC) and ... Cited by 6 - Related articles - All 3 versions
N Marx, D Walcher - Progress in Lipid Research, 2007 - Elsevier Activation of the nuclear transcription factor peroxisome proliferator-activated
receptor-gamma (PPARγ) plays an important role in adipogenesis, insulin
resistance, and glucose homeostasis. Activators of PPARγ include the anti- ... Cited by 4 - Related articles - All 2 versions
D Wright, L Sutherland - Applied Physiology, Nutrition, and Metabolism, 2008 - article.pubs.nrc-cnrc.gc.ca Abstract: The incidence of type 2 diabetes has increased dramatically over the
past several decades and this trend is pro- jected to continue into the
foreseeable future. Skeletal muscle insulin resistance is thought to be a ... Cited by 4 - Related articles - BL Direct - All 3 versions
HD Je, SY Park, AL Barber, UD Sohn - Archives of pharmacal research, 2007 - Springer The present study was undertaken to determine whether rosiglitazone treatment
influences on the agonist-induced or spontaneous regulation of vascular smooth
muscle contraction and, if so, to investigate the related mechanism. ... Cited by 3 - Related articles - BL Direct - All 5 versions
